Impact News +++ Entera Bio GAAP EPS of -$0.25 beats by $0.03, revenue of $0.04M in-line (SeekingAlpha) +++ ENTERA BIO Aktie +4,90%

ARMATA Aktie

>ARMATA Aktienkurs

7.55 EUR -5.6% (TradegateBSX)

Ask: 7.35 EUR / 408 Stück

Bid: 7.3 EUR / 413 Stück

Tagesumsatz: 226 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ARMATA Aktie über LYNX handeln

Intraday

1 Jahr

>ARMATA Performance

1 Woche: +8,6%

1 Monat: -18,4%

3 Monate: +42,5%

6 Monate: +199,6%

1 Jahr: +417,1%

laufendes Jahr: +37,9%

>ARMATA Aktie

Name:

ARMATA PHARMACEUT.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US04216R1023 / A2PKLC

Symbol/ Ticker:

TG1N (Frankfurt)

Kürzel:

FRA:TG1N, ETR:TG1N, TG1N:GR

Index:

Webseite:

https://www.armatapharma...

Profil:

Armata Pharmaceuticals Inc. is a biotechnology company dedicated to the development of innovative therapies to treat antibiotic-resistant infections. Operating in the healthcare sector, the company fo..
>Volltext..

Marktkapitalisierung:

271.74 Mio. EUR

Unternehmenswert:

510.05 Mio. EUR

Umsatz:

4.25 Mio. EUR

EBITDA:

-25.74 Mio. EUR

Nettogewinn:

-150.66 Mio. EUR

Gewinn je Aktie:

-4.15 EUR

Schulden:

249.68 Mio. EUR

Liquide Mittel:

7.53 Mio. EUR

Operativer Cashflow:

-22.33 Mio. EUR

Bargeldquote:

0.97

Umsatzwachstum:

-16.46%

Gewinnwachstum:

-709.83%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ARMATA

Letzte Datenerhebung:

28.03.26

>ARMATA Kennzahlen

Aktien/ Unternehmen:

Aktien: 36.63 Mio. St.

Frei handelbar: 30.33%

Leerverk. Aktien: -

Rückkaufquote: -0.21%

Mitarbeiter: 61

Umsatz/Mitarb.: 0.07 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 54.34%

Bewertung:

KGV: -

KGV lG: -

KUV: 71.1

KBV: -

PEG-Ratio: -0.01

EV/EBITDA: -

Rentabilität:

Bruttomarge: 68.78%

Gewinnmarge: -3544.03%

Operative Marge: -636.66%

Managementeffizenz:

Gesamtkaprendite: -187.36%

Eigenkaprendite: -

>ARMATA Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika

>ARMATA Chart & Kurs - Tradegate

>ARMATA News

26.03.26 - 09:12	Armata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 21:06	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire)
	LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

19.03.26 - 12:03	Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update (PR Newswire)
	LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

23.02.26 - 14:54	Armata Pharmaceuticals: Aktie legt nach FDA-Sonderstatus zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 13:06	Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 (PR Newswire)
	Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority review LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals,......

13.01.26 - 13:03	Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus (PR Newswire)
	FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3 study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the......

27.12.25 - 12:51	Armata: Russland verlagert T-14-Technologie auf ältere Panzermodelle (Golem)
	Der russische Kampfpanzer T-14 Armata scheint vor dem Ende zu stehen. Angeblich soll die Technologie in ältere Panzermodelle eingebaut werden. (Militär, Politik)...

18.11.25 - 13:03	Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST (PR Newswire)
	LOS ANGELES, Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

13.11.25 - 06:51	Armata Pharmaceuticals GAAP EPS of -$0.74, revenue of $1.16M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 01:00	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
	Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.11.25 - 22:06	Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
	LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

10.11.25 - 13:03	Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California (PR Newswire)
	LOS ANGELES, Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

23.10.25 - 14:30	Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? (Zacks)
	Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

23.10.25 - 08:51	XFRA: TG1N: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN ARMATA PHARMACEUT. TG1N US04216R1023 AB/FROM ONWARDS 23.10.2025 08:01 CET...

22.10.25 - 19:12	Armata surges on mid-stage trial data for antibacterial agent (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.10.25 - 18:18	Armata-Aktie schießt nach positiven Phase-2a-Studienergebnissen in die Höhe/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.10.25 - 17:12	Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ (PR Newswire)
	LOS ANGELES, Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

22.10.25 - 17:03	XFRA: TG1N: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ARMATA PHARMACEUT. TG1N US04216R1023 BAW/UFN...

22.10.25 - 16:57	XFRA: INSTRUMENT_SUSPENSION - US04216R1023 (XETRA)
	Instrument ID [7419] (TG1N - US04216R1023) suspended...

14.10.25 - 13:03	Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ (PR Newswire)
	LOS ANGELES, Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Am meisten Platz ist zu Hause. - Sprichwort Serbien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram